These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 2968071)
1. [Oral cytostatic agents in the prevention of urothelial carcinoma. Our experience]. Gelabert Mas A; Arango Toro O; Rosales Bordes A; Coronado García J; Fernández Zuazu J Arch Esp Urol; 1988 Mar; 41(2):135-8. PubMed ID: 2968071 [No Abstract] [Full Text] [Related]
2. Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Jucglà A; Sais G; Navarro M; Peyri J Arch Dermatol; 1995 Mar; 131(3):364-5. PubMed ID: 7887678 [No Abstract] [Full Text] [Related]
3. Acral lentiginosis associated with tegafur/gimeracil/oteracil (TS-1). Park YJ; Soh BW; Lee ES Eur J Dermatol; 2017 Apr; 27(2):209-210. PubMed ID: 28251899 [No Abstract] [Full Text] [Related]
4. [Prospective study of the results at 2 years of one or two cycles of BCG endovesical instillations in the urothelial tumors of the bladder pT1 G3 after completed transurethral resection]. Rischmann P; Gamé X; Mazerolles C; Bittard H; Bouchot O; Descottes JL; Chopin D Prog Urol; 2005 Dec; 15(6 Suppl 1):1266-70. PubMed ID: 16734216 [No Abstract] [Full Text] [Related]
6. [Clinical experience of tegafur-uracil (UFT) against bladder cancer and renal cell carcinoma]. Nakagami Y; Lin TT; Ito H; Hirasawa S; Tannawa K; Fujioka Y; Ogawa H; Tanaka K; Yamada N; Ishii Y Hinyokika Kiyo; 1987 Oct; 33(10):1728-32. PubMed ID: 3128071 [TBL] [Abstract][Full Text] [Related]
7. [Dermatologic toxicity to sorafenib]. Velázquez D; de la Cueva P; Zamberk P; Lázaro P Actas Dermosifiliogr; 2009; 100(6):518-20. PubMed ID: 19709563 [No Abstract] [Full Text] [Related]
8. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report. Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990 [TBL] [Abstract][Full Text] [Related]
9. [Successful inhibition of bladder tumor recurrence by oral administration of UFT]. Nakamoto T; Igawa M; Usui T Gan To Kagaku Ryoho; 1994 Apr; 21(5):697-9. PubMed ID: 8154896 [No Abstract] [Full Text] [Related]
11. Dermatitis due to mitomycin C bladder instillations: study of 2 cases. Arregui MA; Aguirre A; Gil N; Goday J; Ratón JA Contact Dermatitis; 1991 May; 24(5):368-70. PubMed ID: 1832619 [No Abstract] [Full Text] [Related]
12. Adjuvant therapy with 5-fluoro-1-(2-tetrahydrofuryl)-2,4 (1H,3H)-pyrimidinedione (UFT) and Bestatin in patients with transitional cell carcinoma of the bladder--comparison between UFT therapy alone and UFT therapy in combination with Bestatin. Uchibayashi T; Kunimi K; Yamamoto H; Koshida K Int J Clin Pharmacol Ther; 1995 Aug; 33(8):465-8. PubMed ID: 8556228 [TBL] [Abstract][Full Text] [Related]
13. [Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group]. Uchida K; Takeshima H; Kikuchi K; Shimazui T; Miyanaga N; Kawai K; Akaza H; Tsuchiya A; Noguchi R; Hattori K; Manabe F; Matsuki K; Suzuki R; Ishikawa S; Kondo F; Kobayashi T; Koiso K Gan To Kagaku Ryoho; 1998 Jul; 25(8):1179-87. PubMed ID: 9679581 [TBL] [Abstract][Full Text] [Related]
14. [Effect of combination chemotherapy of tegafur, adriamycin and cisplatin on patients with advanced relapsing prostatic carcinoma and advanced bladder tumor]. Yoshida K; Nakame Y; Horiuchi S; Kaneoya F; Kuroda T; Tanoiri A; Koizumi M; Takahashi M; Negishi T; Saitoh H Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1083-5. PubMed ID: 3083786 [No Abstract] [Full Text] [Related]
15. Pre-cystectomy chemotherapy with sequentially administered cisplatin, cyclophosphamide and adriamycin in invasive transitional cell carcinoma of the bladder (preliminary report). Guazzieri S; Sperandio P; Fandella A; Garbeglio A; Pegoraro V; Chiarion V; Fiorentino M; Pagano F Prog Clin Biol Res; 1988; 260():599-602. PubMed ID: 3362909 [No Abstract] [Full Text] [Related]
16. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211 [TBL] [Abstract][Full Text] [Related]